16 October, 2018Success of the first trial of Opsumit (Actelion) in portopulmonary hypertensionSource: redaccionmedica.com Actelion Pharmaceuticals has announced the results of the first randomized controlled trial in portopulmonary hypertension (HTPP). This study has shown that Opsumit (macitentan) significantly […]